Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT-EHA CAR-T 2019 | CD123 CAR-T therapy for the treatment of AML

Elizabeth Budde • 8 Mar 2019
EBMT-EHA CAR-T 2019
Acute Myeloid Leukemia Leukemia CAR-T

Elizabeth Budde, MD, PhD City of Hope National Medical Center, Duarte, CA, speaks at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA) and discusses the results of a recent trial investigating CD123 CAR T-cell therapy for relapsed/refractory acute myeloid leukemia.

More from Elizabeth Budde

5:25
Pivotal findings from a Phase I/II trial of mosunetuzumab monotherapy for R/R follicular lymphoma
Elizabeth Budde • 10 Dec 2021
1:25
CAR T-cell therapy: AML adverse events and optimization
Elizabeth Budde • 8 Mar 2019
1:13
The challenges in treating AML with CAR T-cell therapy
Elizabeth Budde • 28 Feb 2019
0:52
The future of CAR T-cell therapy for AML
Elizabeth Budde • 28 Feb 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals